This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity

"Participants will receive 13 once-weekly subcutaneous injections of MET097 as follows:~* 12 once-weekly doses of 0.6mg followed by a 13th dose of 1.2mg~* 12 once-weekly doses of 0.6mg followed by a 13th dose of 2.4 mg~* 12 once-weekly doses of 0.8 mg followed by a 13th dose of 1.6 mg~* 12 once-weekly doses of 0.8 mg followed by a 13th dose of 3.2 mg~* 12 once-weekly doses of 1.0 mg followed by a 13th dose of 2.0 mg~* 12 once-weekly doses of 1.0 mg followed by a 13th dose of 4.0 mg~* 12 once-weekly doses of 1.2 mg followed by a 13th dose of 2.4 mg~* 12 once-weekly doses of 1.2 mg followed by a 13th dose of 4.8 mg~* Titration regimen of 0.4mg/0.8mg/1.2mg with 4 doses at each dose-level, followed by a 13th dose of 2.4mg~* Titration regimen of 0.4mg/0.8mg/1.2mg with 4 doses at each dose-level, followed by a 13th dose of 4.8mg"

Participants will receive 13 once-weekly subcutaneous injections of matching placebo